|
業務類別
|
Biotechnology |
|
業務概覽
|
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to targetcertain harmful proteins causing oncology and neurology-related diseases. |
| 公司地址
| 395 Winchester Avenue, 5 Science Park, New Haven, CT, USA, 06511 |
| 電話號碼
| +1 203 535-1456 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.arvinas.com |
| 員工數量
| 246 |
| Dr. Noah Berkowitz, M.D.,PhD |
Chief Medical Officer |
美元 421.83K |
29/04/2025 |
| Mr. Andrew R. Saik |
Chief Financial Officer and Treasurer |
美元 272.60K |
24/02/2026 |
| Mr. David K. Loomis |
Vice President and Chief Accounting Officer |
-- |
24/02/2026 |
| Dr. Angela Cacace, PhD |
Chief Scientific Officer |
美元 464.75K |
29/04/2025 |
| Mr. Randy Teel, PhD |
Director, President and Chief Executive Officer |
美元 475.00K |
12/02/2026 |
|
|
| Mr. John Douglas Young |
Independent Director |
29/04/2025 |
| Ms. Leslie V. Norwalk, Esq. |
Independent Director |
24/02/2026 |
| Dr. Briggs W. Morrison, M.D. |
Chairman of the Board |
12/02/2026 |
| Ms. Linda C. Bain |
Independent Director |
24/02/2026 |
| Dr. Laurie Smaldone Alsup, M.D. |
Independent Director |
24/02/2026 |
| Mr. Randy Teel, PhD |
Director, President and Chief Executive Officer |
12/02/2026 |
| Dr. John G. Houston, PhD |
Director |
12/02/2026 |
| Mr. Edward Kennedy, Jr |
Independent Director |
24/02/2026 |
| Dr. Sunil Agarwal, M.D. |
Independent Director |
24/02/2026 |
| Mr. Everett V. Cunningham |
Independent Director |
24/02/2026 |
|
|
|
|
